Apellis Pharmaceuticals Inc. (NASDAQ:
APLS) ranks among the
most oversold biotech stocks to invest in. On November 3, Mizuho maintained its Neutral rating for Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and reduced its price target from $24 to $19. Despite encouraging early results from Empaveli’s launch in C3G/IC-MPGN indications, Mizuho attributed the revision largely to ongoing growth issues with Syfovre, Apellis’ medication for eye disease.
In Q3 2025, Syfovre’s revenue totaled $150.9 million, a minor decrease from $152.0 million in Q3 2024. Despite this minor fall, the company reported a 4% quarter-over-quarter gain in injections. Apellis Pharmaceuticals Inc. (NASDAQ:APLS) stated that SYFOVRE retains over 60% market share in the GA treatment area, with 52% of new patient starts in Q3 2025.
Mizuho has cut its Syfovre revenue projections, now projecting a peak annual revenue of about $800 million, 25–30% lower than the consensus estimates.
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes novel therapeutic compounds to treat diseases with high unmet needs.
While we acknowledge the potential of APLS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the
best short-term AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None. This article is originally published at
Insider Monkey.
